Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation

NCT02485535 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02485535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02485535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Completed
Start date
September 4, 2015
Completion date
July 31, 2020
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, de novo myelodysplastic syndrome, myelodysplastic syndrome, secondary acute myeloid leukemia, secondary myelodysplastic syndrome